Novartis Offers Positive Data On Cardiovascular Drug Entresto
Zacks Investment Research | Nov 16, 2016 07:59AM ET
Novartis AG (NYSE:NVS) announced new analysis of the PARADIGM-HF study on its cardiovascular drug, Entresto, at a scientific session of the American Heart Association (AHA).
Findings from the study demonstrated that Entresto reduced the risk of first and repeated heart failure hospitalizations as well as cardiovascular (CV) deaths that followed heart failure hospitalization by 20–24%, in comparison with enalapril, in heart failure patients with reduced ejection fraction (HFrEF).
We remind investors that in Sep 2016, the company revealed post-hoc analyses from the abovementioned study which demonstrated that patients on Entresto reported a higher quality of life scores compared with those taking enalapril.
Note that Entresto (twice-daily) is used in conjunction with other heart failure therapies for reducing strain on the failing heart. It is indicated in the U.S. for the treatment of heart failure (NYHA class II–IV) in patients with systolic dysfunction. In the EU, the drug is approved for the treatment of symptomatic chronic HFrEF in adult patients.
Novartis expects Entresto to generate sales of approximately $200 million in 2016. Heart failure, a debilitating and life-threatening condition, affects more than 60 million individuals across the world.
Meanwhile, the company continues to work on expanding Entresto’s label and is evaluating the drug for acute decompensated heart failure, and preserved ejection fraction heart failure conditions.
Approval of new drugs and label expansion of existing ones should bode well for Novartis as it has been facing stiff generic competition for some of its key drugs like Gleevec in recent times. Additionally, its oncology drugs are facing competition from immuno-oncology therapies.
NOVARTIS AG-ADR Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.